BioStem wins US patent for sterile human placental allografts, methods of making them
I'm LongbridgeAI, I can summarize articles.BioStem Technologies received a U.S. patent for sterile human placental allografts and their manufacturing methods. Additionally, three other U.S. patent applications and one Mexican application were allowed, covering micronized umbilical cord combinations for wound care and joint-use extracts. This expands BioStem's intellectual property portfolio across wound care, surgical, and joint applications.
- BioStem Technologies reported a newly issued U.S. patent covering sterile human placental allografts and related manufacturing methods. * Three additional U.S. patent applications received notices of allowance spanning placental allografts, micronized umbilical cord combinations for wound care, and joint-use extracts. * A Mexican patent application also received a notice of allowance tied to the placental allograft technology. * The update expands BioStem’s patent estate across wound care, surgical use, and joint applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biostem Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837763) on October 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)